Funatsu, M.; Higashijima, F.; Ariyoshi, N.; Haraguchi, A.; Wasai, Y.; Mikuni, M.; Ohta, M.; Wakuta, M.; Hirano, S.; Yamauchi, K.;
et al. Switching to High-Dose Aflibercept (8 mg) with Pro Re Nata Reduces Treatment Burden in Diabetic Macular Edema: A Real-World Pilot Study. J. Clin. Med. 2026, 15, 2210.
https://doi.org/10.3390/jcm15062210
AMA Style
Funatsu M, Higashijima F, Ariyoshi N, Haraguchi A, Wasai Y, Mikuni M, Ohta M, Wakuta M, Hirano S, Yamauchi K,
et al. Switching to High-Dose Aflibercept (8 mg) with Pro Re Nata Reduces Treatment Burden in Diabetic Macular Edema: A Real-World Pilot Study. Journal of Clinical Medicine. 2026; 15(6):2210.
https://doi.org/10.3390/jcm15062210
Chicago/Turabian Style
Funatsu, Masahiko, Fumiaki Higashijima, Nobuaki Ariyoshi, Aiko Haraguchi, Yuki Wasai, Masanori Mikuni, Manami Ohta, Makiko Wakuta, Shinji Hirano, Kazuhiko Yamauchi,
and et al. 2026. "Switching to High-Dose Aflibercept (8 mg) with Pro Re Nata Reduces Treatment Burden in Diabetic Macular Edema: A Real-World Pilot Study" Journal of Clinical Medicine 15, no. 6: 2210.
https://doi.org/10.3390/jcm15062210
APA Style
Funatsu, M., Higashijima, F., Ariyoshi, N., Haraguchi, A., Wasai, Y., Mikuni, M., Ohta, M., Wakuta, M., Hirano, S., Yamauchi, K., & Kimura, K.
(2026). Switching to High-Dose Aflibercept (8 mg) with Pro Re Nata Reduces Treatment Burden in Diabetic Macular Edema: A Real-World Pilot Study. Journal of Clinical Medicine, 15(6), 2210.
https://doi.org/10.3390/jcm15062210
